We gingen langs op de pediatrie in ziekenhuizen Imelda & Sint-Maarten en hadden voor elk kindje een verrassing 🎁
Met Hartslag25 zorgden we voor meer dan 50 pakketten om bij zoveel mogelijk kinderen in het ziekenhuis doorbrengen, toch een lach op hun gezicht te toveren 🪄🥰
Patrick en Lion vragen het zo lief, die kan je toch niks weigeren 😏
Bekijk het hele knotsgekke interview met onze twee Duitsers binnenkort op YouTube.
Tickets kan je kopen via 👉 bit.ly/TicketsvsEupen#trotsoponzekleuren
To the #CIDP community: thank you. Our ADHERE trial wouldn’t have been successful without the efforts of the @gbscidp and the CIDP community. It is because of you that we can potentially bring #immunology innovations to people with #RareDiseases.
#TogetherWeDiscover#NeuroTwitter
#BreakingNews: We’ve received #FDA approval of the subcutaneous formulation of our FcRn blocker for anti-acetylcholine receptor (AchR) antibody positive generalized myasthenia gravis in adults. Discover more here: bit.ly/3CFZoIy
Four #argonauts co-authored a new paper with our industry peers in @frontiersin, exploring the benefits of support systems for people living with #MG – and the reality that many aren’t able to utilize these services.
Discover more here: bit.ly/3BSvSiz#MGAwarenessMonth
Het SPOQ fandorp ontwaakt... 💛❤️
Nog tot 12u45 kan je terecht in het fandorp voor frisse pintjes, merchandise en vooral heel veel sfeer 🥳
📸 An Rogier & Inge Smits
#trotsoponzekleuren#wegaanmetznallen#VoorLei
What a start to the day at #AANAM! The #argonauts attended the Run/Walk for Brain Research along the Boston waterfront to support key research programs.
Now back to our booth (#2383) to continue meeting leaders in #neuromuscular disorders.
#TogetherWeDiscover#neurology
The resilience of the #RareDisease community has driven Peter Ulrichts, Chief Scientific Officer, and his colleagues since the early days of argenx.
Watch below to discover more about his argenx journey.
#TogetherWeDiscover#BiotechCareers#culture#careers
“We are excited to present our ITP data in a plenary session at ASH, giving us the opportunity to highlight the potential of a new approach to treating this rare disease.” - Luc Truyen, M.D., Ph.D., Chief Medical Officer
Learn more: bit.ly/3uFlmaE#TogetherWeDiscover
#BreakingNews: We’re pleased to announce the U.S. FDA has accepted the Biologics License Application (BLA) for our FcRn blocker for priority review.
Discover more here: lnkd.in/ghYsVTw2#TogetherWeDiscover
Today, we announced our third-quarter 2022 financial results and provided a business update and outlook for the remainder of the year.
Discover more here: argenx.com/investors/events-…#TogetherWeDiscover
How can we make health care more delightful? Join SAS and health care visionary Dr. Koen Kas for an out-of-the-box discussion about improving health care delivery models via #digitaltwins and delight thinking. #TheHealthPulse2.sas.com/6019zdhdx
#DYK that only about 5 percent of #cancer patients have access to clinical trials? Join SAS and Dr. @SeanKhozin to learn more about treatment for all patients through the use of real-world evidence support tools in near real-time. #TheHealthPulse2.sas.com/6011zV8TB
ALT The Health Pulse Podcast website image - Season 3 Episode 1